Apr 25, 2023 / 03:30PM GMT
Brad Canino - Stifel Financial Corp. - Analyst
Hey. I'm Brad Canino, senior analyst here at Stifel. Thanks again for joining us on our first day of the targeted oncology days we're hosting here across several of my analyst colleagues. Happy to continue the fireside chat sessions here with Blueprint. I'm really delighted to have Percy Carter, Chief Scientific Officer; Fouad Namouni, the President, Research & Development. Thank you both for joining us today.
Fouad Namouni - Blueprint Medicines Corporation - President, Research & Development
Thank you, Brad. Happy to be here.
Questions and Answers:
Brad Canino - Stifel Financial Corp. - AnalystI think we're going to keep this conversation pretty asset focused in line with the theme of the event as well. No, questions on ISM, but I'm sure there's a lot of transcripts even from some Stifel conferences recently that cover a lot of those questions. So, on the oncology franchise, I'll start with BLU-945 for frontline EGFR-mutant non-small cell lung cancer.
Trustpilot
